Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yoon Sim Yap

Showing results (71-80 of 92) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2024
Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerYen-Shen Lu, Eznal Izwadi Bin Mohd Mahidin, Hamdy Azim, et al.
Oncotarget|March 22, 2018
Evaluation of three polygenic risk score models for the prediction of breast cancer risk in Singapore ChineseClaire Hian Tzer Chan, Prabhakaran Munusamy, Sau Yeen Loke, et al.
Nature Medicine|October 3, 2017
Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrenceJian Yuan Goh, Min Feng, Wenyu Wang, et al.
Frontiers in Neurology|January 11, 2021
Impact of Cryotherapy on Sensory, Motor, and Autonomic Neuropathy in Breast Cancer Patients Receiving Paclitaxel: A Randomized, Controlled TrialDing Quan Ng, Chia Jie Tan, Boon Chua Soh, et al.
BMC Medicine|March 17, 2022
HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysisRyan Shea Ying Cong Tan, Whee Sze Ong, Kyung-Hun Lee, et al.
Neuro-Oncology|August 21, 2015
Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancerTerence Ng, Shu Mei Teo, Hui Ling Yeo, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 14, 2024
Outcomes in Nonmetastatic Hormone Receptor-Positive HER2-Negative Pure Mucinous Breast Cancer: A Multicenter Cohort StudyRyan Ying Cong Tan, Whee Sze Ong, Kyung-Hun Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2020
Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive CancersSoo-Chin Lee, Noriko Shimasaki, Joline S J Lim, et al.
Molecular Neurobiology|November 2, 2018
Replication and Meta-analysis of the Association between BDNF Val66Met Polymorphism and Cognitive Impairment in Patients Receiving ChemotherapyChia Jie Tan, Sheree Wan Ting Lim, Yi Long Toh, et al.
Breast Cancer Research and Treatment|September 23, 2021
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimensMing Shen Dai, Yin Hsun Feng, Shang Wen Chen, et al.
Pageof 10

Showing results (71-80 of 92) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 21, 2024
Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast CancerYen-Shen Lu, Eznal Izwadi Bin Mohd Mahidin, Hamdy Azim, et al.
Oncotarget|March 22, 2018
Evaluation of three polygenic risk score models for the prediction of breast cancer risk in Singapore ChineseClaire Hian Tzer Chan, Prabhakaran Munusamy, Sau Yeen Loke, et al.
Nature Medicine|October 3, 2017
Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrenceJian Yuan Goh, Min Feng, Wenyu Wang, et al.
Frontiers in Neurology|January 11, 2021
Impact of Cryotherapy on Sensory, Motor, and Autonomic Neuropathy in Breast Cancer Patients Receiving Paclitaxel: A Randomized, Controlled TrialDing Quan Ng, Chia Jie Tan, Boon Chua Soh, et al.
BMC Medicine|March 17, 2022
HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysisRyan Shea Ying Cong Tan, Whee Sze Ong, Kyung-Hun Lee, et al.
Neuro-Oncology|August 21, 2015
Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancerTerence Ng, Shu Mei Teo, Hui Ling Yeo, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 14, 2024
Outcomes in Nonmetastatic Hormone Receptor-Positive HER2-Negative Pure Mucinous Breast Cancer: A Multicenter Cohort StudyRyan Ying Cong Tan, Whee Sze Ong, Kyung-Hun Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 12, 2020
Phase I Trial of Expanded, Activated Autologous NK-cell Infusions with Trastuzumab in Patients with HER2-positive CancersSoo-Chin Lee, Noriko Shimasaki, Joline S J Lim, et al.
Molecular Neurobiology|November 2, 2018
Replication and Meta-analysis of the Association between BDNF Val66Met Polymorphism and Cognitive Impairment in Patients Receiving ChemotherapyChia Jie Tan, Sheree Wan Ting Lim, Yi Long Toh, et al.
Breast Cancer Research and Treatment|September 23, 2021
Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimensMing Shen Dai, Yin Hsun Feng, Shang Wen Chen, et al.
Pageof 10